CASI in AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY

~ CASI to receive upfront payment of $10 million in two instalments ~

~ CASI through its wholly-owned PRC subsidiary, will hold 15% equity of TIANSHI ~

https://finance.yahoo.com/news/casi-pharmaceuticals-enteres-sublicense-agreement-110000564.html